Flagship Ventures Fund V General Partner Llc - Net Worth and Insider Trading

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Foghorn Therapeutics Inc (FHTX). Other recent insider transactions involving Foghorn Therapeutics Inc (FHTX) include a net sale of 311,297 shares made by Samuel Agresta , and a net sale of 11,000 shares made by Fanny Cavalie .

In summary, during the past 3 months, insiders sold 11,000 shares of Foghorn Therapeutics Inc (FHTX) in total and bought 0 shares, with a net sale of 11,000 shares. During the past 18 months, 322,297 shares of Foghorn Therapeutics Inc (FHTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 322,297 shares.

Foghorn Therapeutics Inc (FHTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Codiak BioSciences Inc (CDAKQ). Other recent insider transactions involving Codiak BioSciences Inc (CDAKQ) include a net sale of 61,535 shares made by Douglas E Williams , a net sale of 20,226 shares made by Linda Bain , and a net sale of 17,534 shares made by Sriram Sathyanarayanan .

In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 129,081 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 129,081 shares.

Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

In summary, during the past 3 months, insiders sold 0 shares of Kaleido Biosciences Inc (KLDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kaleido Biosciences Inc (KLDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kaleido Biosciences Inc (KLDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Evelo Biosciences Inc (EVLO). Other recent insider transactions involving Evelo Biosciences Inc (EVLO) include a net sale of 103,730 shares made by Mark Bodmer , a net sale of 80,121 shares made by Duncan Mchale , and a net sale of 46,345 shares made by Marella Thorell .

In summary, during the past 3 months, insiders sold 0 shares of Evelo Biosciences Inc (EVLO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 46,837 shares of Evelo Biosciences Inc (EVLO) were sold and 5,411,255 shares were bought by its insiders, resulting in a net purchase of 5,364,418 shares.

Evelo Biosciences Inc (EVLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 106,621 shares made by Alexander O. Schuth , a net sale of 42,800 shares made by Carole Ho , and a net sale of 186,802 shares made by Ryan J. Watts .

In summary, during the past 3 months, insiders sold 136,870 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 136,870 shares. During the past 18 months, 500,892 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 500,892 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Rubius Therapeutics Inc (RUBY). Other recent insider transactions involving Rubius Therapeutics Inc (RUBY) include a net sale of 15,688 shares made by Pablo J Cagnoni , a net sale of 14,263 shares made by Dannielle Appelhans , and a net sale of 2,593 shares made by Laurence A. Turka .

In summary, during the past 3 months, insiders sold 0 shares of Rubius Therapeutics Inc (RUBY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 32,544 shares of Rubius Therapeutics Inc (RUBY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 32,544 shares.

Rubius Therapeutics Inc (RUBY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Sana Biotechnology Inc (SANA). Other recent insider transactions involving Sana Biotechnology Inc (SANA) include a net sale of 949,000 shares made by Flagship Ventures Fund V, L.p. , a net purchase of 1,818,181 shares made by Arch Venture Fund X Overage, L.p. , and a net purchase of 1,818,181 shares made by Keith Crandell .

In summary, during the past 3 months, insiders sold 25,000 shares of Sana Biotechnology Inc (SANA) in total and bought 5,454,543 shares, with a net purchase of 5,429,543 shares. During the past 18 months, 1,049,000 shares of Sana Biotechnology Inc (SANA) were sold and 5,454,543 shares were bought by its insiders, resulting in a net purchase of 4,405,543 shares.

Sana Biotechnology Inc (SANA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Sigilon Therapeutics Inc (SGTX). Other recent insider transactions involving Sigilon Therapeutics Inc (SGTX) include a net purchase of 1,718,493 shares made by Lilly Eli & Co ,

In summary, during the past 3 months, insiders sold 0 shares of Sigilon Therapeutics Inc (SGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sigilon Therapeutics Inc (SGTX) were sold and 1,718,493 shares were bought by its insiders, resulting in a net purchase of 1,718,493 shares.

Sigilon Therapeutics Inc (SGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Over the past 18 months, Flagship Ventures Fund V General Partner Llc made no insider transaction in Omega Therapeutics Inc (OMGA). Other recent insider transactions involving Omega Therapeutics Inc (OMGA) include a net sale of 40,000 shares made by Richard A Young , and a net purchase of 3,323,310 shares made by Flagship Pioneering Special Opportunities Fund Ii General Partner Llc .

In summary, during the past 3 months, insiders sold 0 shares of Omega Therapeutics Inc (OMGA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 40,000 shares of Omega Therapeutics Inc (OMGA) were sold and 3,323,310 shares were bought by its insiders, resulting in a net purchase of 3,283,310 shares.

Omega Therapeutics Inc (OMGA)'s detailed insider trading history can be found in Insider Trading Tracker table.